Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Alcon Inc. Ordinary Shares (NY:ALC)

67.79 +1.67 (+2.53%)
Streaming Delayed Price Updated: 3:36 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden. 
Via MarketBeat
News headline image
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Alcon Analysts Increase Their Forecasts After Q2 Results ↗
 
Via Benzinga
News headline image
ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024 ↗
ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Analysts Increase Their Forecasts Following Q1 Results ↗
 
Via Benzinga
Alcon Inc. (NYSE: ALC) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
S&P 500, Nasdaq Extend Gains For 8th Consecutive Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone ↗
 
Via Benzinga
Topics Stocks
News headline image
Lowe's, Palo Alto Networks And 3 Stocks To Watch Heading Into Tuesday ↗
 
Via Benzinga
News headline image
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED ↗
Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to... 
Via Talk Markets
News headline image
US Stocks Trim Gains As Iran Mulls Attack On Israel; Gold, Oil Rally: What's Driving Markets Monday? ↗
Wall Street turns negative due to geopolitical risks. Gold rises 1.5% and stocks edge higher. Scotiabank acquires minority stake in KeyCorp. 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Climb After Volatile Week As Traders Eye Inflation Data and Retail Earnings: Strategist Says Not CPI But This Data Can Give People Lot Of Conviction ↗
The resilience of the market was in full display on Monday after last week’s “historical comeback” by the market. The major index futures traded higher, albeit by a modest magnitude. 
Via Benzinga
Topics Economy Stocks
News headline image
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock? ↗
Johnson & Johnson has beaten earnings per share in more than 10 straight quarters. Will the trend continue in Q2? 
Via Benzinga
News headline image
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
From Alcon Inc. Investors
Via Business Wire
News headline image
ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q1 2024 ↗
ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Do You Have Your Eye On Vision Care Stocks? ↗
For investors seeking stable and growing opportunities, eye care stocks are an attractive option. 
Via Talk Markets
News headline image
MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio? ↗
Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news. 
Via Benzinga
News headline image
Contact Lens Maker Alcon's Has New Growth Avenues, Analyst Upgrades Stock ↗
Alcon's recent upgrades and promising opportunities, including the BELKIN Vision acquisition, expanding glaucoma treatment options, enhanced PanOptix IOL, and market advancements in China. 
Via Benzinga
News headline image
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
2 Intriguing Medical Stocks To Buy For Steady Growth As Earnings Approach ↗
Among the medical sector, Alcon and Prestige Consumer Healthcare are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14. 
Via Talk Markets
News headline image
Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
From Alcon Inc. Investors
Via Business Wire
News headline image
Alcon Announces Results of 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
News headline image
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population 
Via MarketBeat
News headline image
Alcon Publishes Agenda for 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
News headline image
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
From Alcon Inc. Corporate
Via Business Wire
News headline image
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
From Alcon Inc. Investors
Via Business Wire
News headline image
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month ↗
"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins... 
Via Benzinga
News headline image
Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: 'Innovation Is Key' ↗
Innovation and digitalization have been in focus among ophthalmology majors. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.